CardiopulmonaryToxicity of ElectronicNicotineDeliverySystems
Project Number1R01HL171763-01
Contact PI/Project LeaderCONKLIN, DANIEL JOSEPH
Awardee OrganizationUNIVERSITY OF LOUISVILLE
Description
Abstract Text
CardiopulmonaryToxicity of ElectronicNicotineDeliverySystems
Although electronicnicotinedeliverysystems (ENDS) are widely used by youth and young adults, the toxicity
and the health effects of these products remain unclear. Many types of devices with varying constituents have
been introduced into the market, making it difficult to ascribe toxicity to a specific class of products or to study
their long-term health effects. ENDS produce volatile organic compounds (VOCs) such as formaldehyde and
acrolein, which are generated by the thermal degradation of e-liquids containing propylene glycol:vegetable
glycerin (PG:VG) and may lead to adverse health effects. Nevertheless, the dependence of VOC generation on
e-liquid composition and constituents, nicotine and other ingredients has not been studied, and the contributions
of different constituents to the potential harmful effects of e-cigarettes remain unclear. Therefore, within the
framework of a regulatory context, we plan to study the cardiovascular and pulmonary toxicity of e-cigarette
aerosols over a wide range of operating conditions and use patterns to provide rigorous and comprehensive data
pertinent to the regulation of new and emerging devices by the US Food and Drug Administration (FDA). Based
on our previous work, we propose that device-specific cardiovascular and pulmonary effects of e-cigarettes are
in large part mediated by the extent of VOCs generation and toxicity, which are modified by co-exposure to
nicotine and other e-liquid ingredients as well as individual use patterns.
Public Health Relevance Statement
CardiopulmonaryToxicity of ElectronicNicotineDeliverySystems
In the proposed studies, we will investigate the cardiovascular and pulmonary toxicity of ENDS using animal
models and state-of-the-art exposure technology, protocols, and biomarkers of exposure and of harm. As such,
we will directly address the Scientific Domain of Toxicity, and thus, will provide the FDA/CTP with rigorous and
validated data to support policies regulating the design, manufacturing, and marketing of e-cigarette devices in
order to protect public health.
No Sub Projects information available for 1R01HL171763-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01HL171763-01
Patents
No Patents information available for 1R01HL171763-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01HL171763-01
Clinical Studies
No Clinical Studies information available for 1R01HL171763-01
News and More
Related News Releases
No news release information available for 1R01HL171763-01
History
No Historical information available for 1R01HL171763-01
Similar Projects
No Similar Projects information available for 1R01HL171763-01